Atlas Trials

Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation

Clinical trial NCT02428296 · COMPLETED

Trial details

NCT number
NCT02428296
Sponsor
National Human Genome Research Institute (NHGRI)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
PIK3CA-Related Overgrowth Spectrum (PROS)Growth DisorderGenetics
Start date
2015-04-23
Primary completion
2018-02-14
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.